Results 41 to 50 of about 3,283 (198)

Neovascular glaucoma at a tertiary Centre in Finland, 2008–2024: A retrospective cohort study

Acta Ophthalmologica, EarlyView.
Abstract Purpose Neovascular glaucoma (NVG) is a refractory secondary glaucoma, yet longitudinal outcome data remain limited. This study reports its aetiologies, treatments and outcomes. Methods Patients with NVG were identified through electronic medical record review.
Gilbert Simons, Mikael von Fersen, Paula Summanen, Mika Harju   +3 more
wiley   +1 more source

Efficacy of Initial Intravitreal Faricimab Injection after Switching from Aflibercept to Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration

Ophthalmic Research
Introduction: Previous studies have demonstrated the efficacy of faricimab where the intervention in treatment-resistant neovascular age-related macular degeneration (nAMD) had been switched from aflibercept to faricimab.
Yutao Du, Yasmine Sahraie, Meg Das, Andreas Katsimpris   +3 more
doaj   +1 more source

Predictors of visual acuity, intraocular pressure and pain in neovascular glaucoma

Acta Ophthalmologica, EarlyView.
Abstract Purpose To identify factors associated with best‐corrected visual acuity (BCVA), intraocular pressure (IOP) and ocular pain in neovascular glaucoma (NVG). Methods The retrospective cohort included all patients diagnosed with NVG during 2008–2024 at Helsinki University Hospital, Finland. Linear mixed‐effects models used pre‐specified covariates,
Gilbert Simons, Mikael von Fersen, Alexandra Dahlberg, Ville Vartiainen, Paula Summanen, Mika Harju   +5 more
wiley   +1 more source

Analysis of the aqueous humor before and after the administration of faricimab in patients with nAMD

Scientific Reports
This study aimed to evaluate the changes in cytokine levels in the aqueous humor and factors of treatment resistance following intravitreal faricimab injection in treatment-naïve patients with neovascular age-related macular degeneration.
Ryo Nonogaki, Hikaru Ota, Jun Takeuchi, Yuyako Nakano, Ai Fujita Sajiki, Takahito Todoroki, Koichi Nakamura, Hiroki Kaneko, Koji M. Nishiguchi   +8 more
doaj   +1 more source

Faricimab Treat-and-Extend Dosing for Macular Edema due to Retinal Vein Occlusion: 72-Week Results From the BALATON and COMINO Trials.

Ophthalmology Retina
PURPOSE To assess the efficacy, durability, and safety of dual angiopoietin-2/vascular endothelial growth factor inhibition with faricimab dosed per a modified treat-and-extend (T&E)-based regimen in patients with retinal vein occlusion (RVO).
Carl J. Danzig, C. Dinah, F. Ghanchi, L.-O. Hattenbach, A. Khanani, Timothy Y. Y. Lai, Masahiko Shimura, Francis Abreu, Pablo Arrisi, Ying Liu, Liliana P. Paris, Anne-Cecile Retiere, Jeffrey R. Willis, P. Schlottmann   +13 more
semanticscholar   +1 more source

Intravitreal faricimab in patients with nAMD: French data from the Fight Retinal Blindness! Registry

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess real‐world outcomes of intravitreal faricimab in French patients with neovascular age‐related macular degeneration (nAMD) previously treated with vascular endothelial growth factor (VEGF) inhibitors using data from the Fight Retinal Blindness! (FRB!) Registry.
Eloi Debourdeau, Déborah Harboun, Pierre‐Henry Gabrielle, Yohei Hashimoto, Chloe Chamard, Frederic Michon, Benjamin Wolff, Héloïse Torres‐Villaros, Audrey Giocanti‐Auregan, Mark Gillies, Catherine Creuzot–Garcher, Vincent Daien   +11 more
wiley   +1 more source

One-year outcomes after switching to faricimab in eyes with pre-treated neovascular age-related macular degeneration: a Swiss Retina Research Network report.

Ophthalmology Retina
PURPOSE To report the efficacy and safety of switching to faricimab in a real-world, Swiss cohort of patients with pre-treated neovascular age-related macular degeneration (nAMD).
Gabriela Grimaldi, A. Ambresin, I. Pfister, Christin Schild, C. Plasencia, K. Hatz, Richard Stillenmunkes, Marion R. Munk, Arianna Paris, M. Menghini, D. Artemiev, Andreas Ebneter, Jennifer Cattaneo, E. C. de Oliveira Figueiredo, C. Eandi, Jacqueline Fröhlich, N. Feltgen, T. Spitznagel, G. M. Somfai, Mariano Cozzi, S. Zweifel, A. Weinberger, Justus G. Garweg   +22 more
semanticscholar   +1 more source

Intraocular Inflammation, Safety Events, and Outcomes After Intravitreal Injection of Ranibizumab, Aflibercept, Brolucizumab, Abicipar Pegol, and Faricimab for nAMD

Journal of VitreoRetinal Diseases
Purpose: To compare the rates of intraocular inflammation (IOI) in patients with neovascular age-related macular degeneration (nAMD) after injection of intravitreal (IVT) antivascular endothelial growth factor drugs.
Marta Stevanovic, Nicole Koulisis, Tom Chen, Stavros N. Moysidis, Bruce Burkemper, Brian C. Toy, Narsing A Rao, Dean Eliott, Mark S. Humayun   +8 more
semanticscholar   +1 more source

Ocular Manifestations of Metabolic Syndrome: A Systemic Vascular Phenotype

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 9809-9818, November 2026.
ABSTRACT Context Metabolic syndrome (MetS) is defined by central obesity, insulin resistance, hypertension and dyslipidemia. MetS affects over one‐third of US adults. Beyond its cardiovascular burden, MetS has clinically relevant associations with ocular health and may contribute to a systemic vascular and neuro‐metabolic phenotype involving the retina,
Ron T. Varghese, Ansu A. John
wiley   +1 more source

Multidimensional evaluation of the potential impact of faricimab availability on healthcare system accessibility for retinal disease treatment in Poland

BMC Health Services Research
Background This study aimed to evaluate the impact of introducing faricimab into a publicly funded drug programme for retinal diseases, focusing particularly on reducing treatment frequency and optimising resources.
Michał Seweryn, Justyna Kopel, Joanna Augustynska, Adam Mikołajewicz, Mario Damiano Toro, Robert Rejdak   +5 more
doaj   +1 more source